Selective estrogen receptor modulators (SERMs): a review of clinical data

Sebastian Mirkin; James H Pickar

doi:10.1016/j.maturitas.2014.10.010

Selective estrogen receptor modulators (SERMs): a review of clinical data

Maturitas. 2015 Jan;80(1):52-7. doi: 10.1016/j.maturitas.2014.10.010. Epub 2014 Oct 23.

Authors

Sebastian Mirkin¹, James H Pickar²

Affiliations

¹ TherapeuticsMD, Boca Raton, FL, USA.
² Obstetrics and Gynecology, Columbia University Medical Center, New York, NY, USA. Electronic address: jhpickar@me.com.

PMID: 25466304
DOI: 10.1016/j.maturitas.2014.10.010

Abstract

SERMs represent a diverse group of molecules with varying levels of estrogenic agonist and antagonist activity in target tissues. SERMs have a long regulatory approval history and have been studied for a variety of therapeutic indications. The clinical effects of SERMs have been evaluated in a large number of phase 3 clinical trials. Many of the available SERMs have proved to be effective as chemo-preventive agents and treatments for breast cancer and a number are useful for the prevention and treatment of osteoporosis. The endometrial effect of SERMs has been a key differentiator in clinical practice and a major hurdle for regulatory approval. The effect of SERMs in the vagina also represents a major distinction among different SERMs. This review summarized key clinical finding of SERMs in different target tissues.

Keywords: Breast cancer; Endometrial cancer; Menopause; Osteoporosis; SERM.

Publication types

Review

MeSH terms

Breast Neoplasms / drug therapy*
Female
Humans
Osteoporosis, Postmenopausal / prevention & control*
Selective Estrogen Receptor Modulators / therapeutic use*
Women's Health

Substances

Selective Estrogen Receptor Modulators